DD 2015.jpg

Don DeGolyer – Founder & Chief Executive Officer

Don DeGolyer is the Founder & Chief Executive Officer of Vertice Pharma and has built a successful and significant career in the pharmaceutical industry.  He was previously the Chief Operating Officer of Endo Pharmaceuticals where he built one of the fastest growing Specialty Pharmaceuticals businesses, completed six acquisitions and created more than $12 Billion dollars of shareholder value. He also served as President & CEO of Sandoz North America at a time when he and his team grew revenues to $3.5 billion establishing Sandoz as the second largest generics company in the world. Don began his career at Pfizer, Johnson & Johnson and then Novartis progressing through various roles of increasing responsibility.  

Ozgur Kilic Vertice Pharmaceutical

Ozgur Kilic – Chief Financial Officer

Ozgur is the Chief Financial Officer of Vertice Pharma. He was most recently Head of Business Planning and Analysis at Alcon North America, Eye Care Division of Novartis. Prior to Alcon, he worked at Sandoz U.S. overseeing commercial, manufacturing, BD&L and R&D Finance. Before coming to the U.S. Ozgur spent 10 years in Europe within Novartis Group in senior finance roles including CFO in the UK and Region Europe CFO.  Ozgur is a qualified Chartered Management Accountant and holds an MBA degree.

Scott Meyers

Scott Meyers - Chief Operating Officer

Scott Meyers is the Chief Operating Officer of Vertice Pharma.  He has over 15 years of pharmaceutical experience, most recently as Vice President, General Manager, Dermatology of Fougera Inc., a Sandoz / Novartis company.   Prior to Fougera, Scott led Strategic Planning & Market Analytics for Sandoz US and worked at McKinsey & Company’s pharmaceutical practice in New Jersey, focusing on R&D and commercial operations.  Scott also worked as a Chemical Engineer for Merck at their West Point, PA site. Scott holds a Master of Business Administration from Northwestern University’s Kellogg School of Management and holds a Master of Chemical Engineering, a Bachelor of Science in Chemical Engineering, and a Bachelor of Arts in Chemistry all from Cornell University.

Noel Greenberger2..JPG

Noel Greenberger – Vice President, Commercial Operations

Noel Greenberger is the Vice President, Commercial Operations of Vertice Pharma.  He was most recently Executive Director of Respiratory at Sandoz U.S., the generics division of Novartis, and was responsible for building and commercializing Sandoz’ portfolio of respiratory medicines.  While at Sandoz, Noel held various leadership roles in Biopharmaceuticals and Strategic Planning. Prior to Sandoz, Noel worked at McKinsey & Company’s healthcare practice and also worked at ZS Associates, focusing on pharmaceutical sales and marketing strategy.  Noel holds a Master of Business Administration from The Wharton School of Pennsylvania and a Bachelor of Science in Industrial Engineering from Northwestern University.



Dr. Nandi is the Vice President, Research & Development at Vertice Pharma and has over 15 years of experience in R&D. Dr. Nandi was most recently Vice President, Generic Research & Development for Impax Laboratories where he was responsible for CMC development activity for Generic and Branded pipeline. Prior to Impax, Dr. Nandi held positions of increasing responsibilities at Sandoz, including last position as Executive Director, Portfolio, Project Management and Scientific Affairs. He also worked in various positions in R&D at Par Pharmaceuticals and Geneva Pharmaceuticals. Dr. Nandi has hands-on experience in Product Development of ANDA including First to File and 505 (b)(2) products in various dosage forms and also extensive experience in Portfolio & Project Management, Development Operations, Licensing, Due Diligence, Remediation Programs and R&D Strategy. He co-authored various scientific publications and patents and patent applications. Dr. Nandi also delivered invited talks in the area of drug delivery and generic portfolio and project management strategy in various national and international symposiums. He holds a Master of Business Administration from Rutgers, State University of NJ; a Ph.D. in Pharmaceutical Sciences from St. John’s University, NY and a Master’s degree in Pharmacy from Birla Institute of Technology and Sciences, India.